Physician profile
Robert L Allison
NPI 1154393742
$5,999.03
in general payments reported to CMS, 2019-2025
28 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $167 · 2021: $27.70 · 2022: $509 · 2023: $1,333 · 2024: $1,256 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $809.79 | 2019-2025 | Mounjaro, Zepbound, Basaglar |
| Amgen INC. | $751.19 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $704.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $648.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $489.32 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.84 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $298.33 | 2021-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $228.89 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Daiichi Sankyo INC. | $216.04 | 2020-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $212.16 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $195.88 | 2019-2024 | Farxiga |
| Medtronic, INC. | $174.53 | 2022-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $130.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $118.72 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $117.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $98.93 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $94.86 | 2024-2025 | |
| Abbvie INC. | $81.08 | 2025 | |
| Grifols USA, LLC | $51.17 | 2019 | |
| Philips North America LLC | $38.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $31.64 | 2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $30.86 | 2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $28.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.22 | 2022 | |
| Inspire Medical Systems, INC. | $19.52 | 2025 | Inspire |
| Axonics, INC. | $17.71 | 2024 | Axonics |
| Amarin Pharma, INC. | $14.83 | 2020 | |
| Solventum Corporation | $13.59 | 2024 | Prevena, V.A.C. Dermatac, V.A.C.Ulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.